Wall Street analysts jumping on Lilly train
For more than two years, Eli Lilly and Co. has pushed the message that the worst days are over and a brighter future is just around the corner. Now, finally, Wall Street is starting to believe.
Pharmaceutical
Articles
Americans getting fed up over high drug prices
A new poll shows that a growing number of people feel drug prices are unreasonable, and they favor a variety of government actions to keep prices down.
Confluence Pharmaceuticals lands $1.3M in venture capital
Indianapolis-based Elevate Ventures said it made the investment through the 21st Century Research & Technology Fund, which is reserved for Indiana companies.
Pills, pens bring hope for drug companies in diabetes crunch
Drugmakers facing a price war in the diabetes market, including Indianapolis-based Eli Lilly and Co., are betting on new technologies to withstand the competition.
Clinton’s drug proposals ‘very negative’ for industry, top CEO says
The head of Pfizer Inc., America’s biggest drugmaker, said Democratic presidential nominee Hillary Clinton’s proposals to contain the price of pharmaceuticals would be “very negative” for the industry and are a step toward single-payer health care.
Under fire, maker of EpiPen launching cheaper, generic version
Mylan will start selling a cheaper version of the emergency allergy treatment after absorbing waves of criticism over a growing list price that made it unaffordable for many patients.
Lilly drug for Alzheimer’s gets fast-tracked by FDA
Named AZD3293, the drug belongs to a novel class of drugs that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
Indiana continues to lead U.S. in pharmacy robberies
There were more pharmacy robberies in Indiana last year than California, which has a population about six times larger.
Incoming Lilly CEO pick to focus globally
Dave Ricks will begin guiding the company during a period of relative calm compared with the trying times John Lechleiter navigated during his eight years at the helm.
Lilly CEO Lechleiter to retire at end of year
John Lechleiter has been the company’s CEO since 2008. The announcement Wednesday morning of his retirement comes one day after the firm announced strong revenue and profit for its second quarter, indicating that Lechleiter’s initiatives have paid off.
Anthem, Express Scripts dispute comes down to pricing
The agreement by Indianapolis-based Anthem Inc. to sell its pharmacy-benefits arm to St. Louis-based Express Scripts for $4.7 billion has turned the companies at each other’s throats, culminating in a multibillion-dollar legal battle that began early this year.
Next president should attack drug prices, Obama says in medical journal
President Barack Obama has written a game plan on health care for the next president, including a crackdown on prescription drug prices that may cut pharmaceutical manufacturers’ profits if adopted.
Lilly stock rises after FDA panel backs new Jardiance label
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
CEO Ellis resigns after 20 years at struggling drug firm Endocyte
The West Lafayette-based company has named CFO and COO Mike Sherman as new CEO and president, but did not give a reason for the abrupt change in leadership.
Biochemist Richard DiMarchi is ‘true entrepreneur’
Biochemist has founded or co-founded five startups since retiring from Eli Lilly and Co. as head of biotechnology research 13 years ago, at age 50.
HOOSIER BEACON: The legacy of Alec Clowes
Upon his arrival in Indianapolis, Clowes began aggressively pursuing research that might lead to mass-produced pharmaceuticals.
Medicare plan on payment for cancer drugs stirs battle
A Medicare proposal to test new ways of paying for chemotherapy and other drugs given in a doctor's office has sparked a furious battle, and cancer doctors are demanding that the Obama administration scrap the experiment.
Insulin’s surging price turns diabetes staple into luxury good
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
Allergan, Pfizer call off proposed record $160B merger
The biggest U.S.-based drugmaker, Pfizer Inc., will stay put thanks to aggressive new Treasury Department rules that succeeded in blocking Pfizer from acquiring rival Allergan and moving to Ireland—on paper—to reduce its tax bill.
Meth law opens door for fledgling drugmaker
A small manufacturer angling to pick up more business in Indiana makes cold and allergy medicine resistant to being abused by methamphetamine makers.